CJC-1295 represents a synthetic analog of growth hormone-releasing hormone (GHRH) that has garnered persistent attention in peptide research communities, primarily due to its structural enhancements over the native peptide. Researchers encounter two principal variants: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (alternatively termed Mod GRF 1-29). Although both variants derive from a shared GHRH-based framework, the inclusion or exclusion of DAC technology profoundly transforms their pharmacokinetic characteristics, binding mechanisms, and the experimental questions they optimally address.
For researchers constructing preclinical study protocols investigating pulsatile versus sustained growth hormone (GH) secretion, pituitary signaling mechanisms, and downstream IGF-1 axis regulation, comprehending the molecular differences between these variants is critical. This guide offers a systematic comparison of both forms, integrating published preclinical evidence and receptor biology to assist laboratory scientists in contextualizing their experimental frameworks. For a broader overview of these peptides, visit Source Peptides.
Research-only notice: This content is presented for educational discussion and laboratory research applications exclusively. No medical claims are stated or implied.
Frequently Asked Questions
What is the main structural difference between CJC-1295 with DAC and CJC-1295 without DAC?
CJC-1295 with DAC contains a lysine-maleimide linker conjugated to a fatty acid chain (the Drug Affinity Complex), enabling covalent binding to serum albumin in vivo. In contrast, CJC-1295 without DAC (Mod GRF 1-29) preserves the core 29-amino-acid GHRH analog sequence but omits this albumin-binding modification, yielding a substantially shorter half-life in preclinical systems.
What does DAC stand for in CJC-1295 with DAC?
DAC designates Drug Affinity Complex. It describes a reactive maleimide group linked to the peptide through a lysine residue that forms a covalent thioether bond with cysteine-34 on circulating serum albumin, effectively utilizing albumin as a carrier to prolong the peptide's circulatory half-life in preclinical systems.
How do the half-lives of CJC-1295 with DAC and without DAC compare in preclinical studies?
Preclinical and early research frameworks have shown that CJC-1295 without DAC exhibits a half-life estimated in minutes (roughly 30 minutes), consistent with endogenous GHRH analogs. CJC-1295 with DAC has demonstrated a markedly prolonged half-life spanning several days in animal models, attributable to its albumin-binding mechanism.
What is Mod GRF 1-29 and how does it relate to CJC-1295 No DAC?
Mod GRF 1-29 is an alternative nomenclature for CJC-1295 without DAC, employed in research literature to designate the 29-amino-acid modified GHRH fragment. Both terms reference the identical compound: a GHRH analog with four strategic amino acid substitutions relative to native GHRH(1-29) that enhance enzymatic stability while maintaining receptor affinity.
Why do researchers combine CJC-1295 No DAC with Ipamorelin in preclinical studies?
Investigators have examined the combination of CJC-1295 No DAC with Ipamorelin because the two peptides target complementary receptor pathways—GHRH receptor and ghrelin/GHS-R1a receptor, respectively. Research indicates this pairing may yield additive or synergistic effects on pulsatile GH release in animal models, replicating physiological GH secretion patterns more faithfully than either compound in isolation.
Is CJC-1295 with DAC suitable for studying sustained GH axis modulation in preclinical models?
Evidence suggests that CJC-1295 with DAC is valuable for investigating prolonged, tonic stimulation of the GHRH receptor pathway in preclinical frameworks due to its extended albumin-bound half-life. This characteristic makes it a pertinent instrument for examining sustained IGF-1 axis responses, as documented in rodent studies analyzing multi-day GH release profiles.
What are the four amino acid substitutions in CJC-1295 No DAC compared to native GHRH(1-29)?
The four substitutions in Mod GRF 1-29 (CJC-1295 No DAC) include: Ala2 → D-Ala2, Gln8 → Ala8, Ala15 → His15 (or comparable variant), and Leu27 → Met27 (contingent on the specific synthesis). These modifications collectively diminish dipeptidyl peptidase IV (DPP-IV) cleavage and oxidative degradation, enhancing the compound's stability in biological matrices for research applications.
Can CJC-1295 with DAC and without DAC be studied together in the same preclinical protocol?
Certain preclinical research protocols have examined both variants within comparative frameworks to contrast pulsatile versus sustained GH secretion paradigms. Researchers studying GH axis biology may design experiments employing each form independently or sequentially to elucidate how release kinetics influence downstream signaling outcomes in animal models.
Structural Biology: What Separates These Two Variants at the Molecular Level
Both CJC-1295 variants derive from the same foundational architecture: a modified 29-amino-acid segment of endogenous GHRH. Native GHRH(1-44) constitutes the hypothalamic peptide responsible for stimulating anterior pituitary somatotrophs to release growth hormone. GHRH(1-29) retains complete receptor agonist activity at the GHRH receptor, and Mod GRF 1-29 (CJC-1295 No DAC) embodies a further stabilized iteration of this fragment with strategic amino acid substitutions to resist proteolytic degradation.
Introducing the DAC modification converts CJC-1295 No DAC into a structurally distinct entity. A reactive maleimide-containing linker attaches to a lysine residue (typically at position 17 or via an appended lysine), conjugated to a long-chain fatty acid. This construct is engineered to react with the free thiol group of cysteine-34 on serum albumin, forming a stable thioether bond. The outcome is an albumin-bound peptide that circulates for an extended period, gradually releasing its bioactive GHRH-agonist component over days in animal models. For additional context on multi-receptor agonist strategies, researchers may find parallels in GLP-3 Retatrutide research, which explores triple receptor agonism mechanisms.
Key Structural Summary
| Feature | CJC-1295 with DAC | CJC-1295 No DAC (Mod GRF 1-29) |
|---|---|---|
| Core sequence | Modified GHRH(1-29) analog | Modified GHRH(1-29) analog |
| DAC modification | Present (maleimide-lysine-fatty acid) | Absent |
| Albumin binding | Covalent thioether bond to Cys-34 | None |
| Approximate half-life (preclinical) | ~5–8 days (animal models) | ~20–30 minutes |
| GH release pattern (preclinical) | Sustained / tonic elevation | Pulsatile / physiological |
| Molecular weight | ~3,647 Da (with DAC linker) | ~3,357 Da |
| Primary research application | Sustained GH/IGF-1 axis studies | Pulsatile GH secretion studies |
Release Kinetics: Pulsatile vs Sustained Paradigms in Preclinical Research
Among the most substantial distinctions between the two variants lies in the GH release kinetics they generate in preclinical models, which holds meaningful implications for experimental design and interpretation.
CJC-1295 No DAC: Pulsatile Release Kinetics
Absent the DAC modification, CJC-1295 No DAC functions much like an enhanced version of endogenous GHRH—it occupies GHRH receptors on pituitary somatotrophs, triggers GH secretion, and is subsequently cleared rapidly from the system. In rodent frameworks, this generates a sharp, pulse-like elevation in circulating GH that mirrors physiological patterns observed with endogenous GHRH signaling.
This pulsatile kinetic profile renders CJC-1295 No DAC particularly valuable for research paradigms investigating timing-sensitivity of GH axis signaling, somatotroph responsiveness, or studies where replicating natural GH secretion architecture is scientifically important. Combining this GHRH analog with a ghrelin receptor agonist has been a prevalent preclinical strategy for investigating amplified pulsatile GH outputs through dual-receptor engagement.
CJC-1295 with DAC: Sustained Tonic Stimulation
The DAC-modified variant presents fundamentally different research utility. By binding to serum albumin shortly after introduction into a biological system, CJC-1295 with DAC creates a long-duration reservoir of GHRH-receptor agonist activity. Preclinical investigations in rodent models have demonstrated that this can sustain elevated IGF-1 and GH levels for multiple days following a single exposure, providing researchers with an instrument for studying chronic GHRH receptor activation without repeated interventions.
A seminal early study by Jetté et al. (2005) examining CJC-1295 with DAC in animal models reported extended GH and IGF-1 elevations consistent with the albumin-binding half-life hypothesis. This sustained kinetic pattern opens distinct research questions about prolonged somatotropic stimulation, hypothalamic feedback regulation, and long-duration IGF-1 axis changes—research questions that the short-acting No DAC variant is poorly suited to address. For comprehensive mechanistic context, see the detailed CJC-1295 with DAC vs No DAC guide, which covers receptor coupling, second messenger cascades, and structural rationale for each amino acid modification.
Preclinical Study Comparisons: What the Research Literature Reveals
Animal Model Findings: CJC-1295 with DAC
The foundational preclinical work on CJC-1295 with DAC was conducted primarily in rodent and canine models. A study published by Jetté et al. in the Journal of Clinical Endocrinology & Metabolism (2005) examined CJC-1295 with DAC in rats and monkeys, reporting dose-dependent increases in plasma GH and IGF-1 levels that persisted for several days. The study's findings were consistent with the anticipated albumin-binding pharmacokinetics and suggested robust GHRH receptor engagement over extended timeframes.
Importantly, the sustained elevation in IGF-1 observed in these models raised research questions about potential desensitization of somatotroph cells under prolonged GHRH receptor stimulation—a topic that continues to be explored in GH axis biology research. Whether tonic versus pulsatile stimulation differentially affects GHRH receptor downregulation is a nuanced question that comparative studies of both CJC variants can help illuminate.
Animal Model Findings: CJC-1295 No DAC
Preclinical research examining CJC-1295 No DAC in isolation has focused primarily on its capacity to amplify pulsatile GH secretion in rodent models. Studies have investigated GHRH receptor occupancy kinetics, the magnitude of GH pulses relative to native GHRH(1-44), and the compound's resistance to DPP-IV cleavage compared to unmodified GHRH fragments.
The pairing of CJC-1295 No DAC with ghrelin receptor agonists like Ipamorelin has been extensively studied. Ipamorelin acts on the GHS-R1a receptor through a distinct signaling pathway to that of GHRH, and preclinical studies have investigated whether these two pathways produce additive GH release when engaged simultaneously in animal models.
Comparative Observations Across Studies
When preclinical findings from both variants are positioned side by side, several patterns emerge in the literature:
- IGF-1 elevation duration: CJC-1295 with DAC studies consistently report multi-day IGF-1 elevations in animal models; No DAC studies report transient elevations aligned with the compound's short half-life.
- GH pulse architecture: No DAC studies preserve discrete GH pulse patterns; DAC studies show a blunted, sustained GH elevation that disrupts normal pulsatile architecture.
- Receptor sensitivity: Some preclinical literature has raised the hypothesis that prolonged GHRH receptor stimulation (as modeled with the DAC variant) may influence receptor desensitization dynamics differently than pulsatile stimulation—though this remains an active area of investigation.
- Downstream signaling: Both variants engage the adenylyl cyclase / cAMP / PKA pathway through GHRH receptor coupling, with differences in downstream signaling duration reflecting their respective kinetic profiles.
Choosing the Right Variant for Your Research Protocol
Choose CJC-1295 with DAC if...
- The research question involves studying sustained, multi-day GH or IGF-1 axis modulation in animal models
- The protocol benefits from less frequent compound administration in preclinical settings
- The study design investigates prolonged GHRH receptor engagement and potential somatotroph desensitization
- The focus is on albumin-binding pharmacokinetics as a delivery mechanism model
Choose CJC-1295 No DAC if...
- The research question specifically involves pulsatile GH secretion dynamics and physiological mimicry
- The protocol requires precise temporal control over GH release timing in in vitro or in vivo models
- The study involves combination with ghrelin receptor agonists (such as Ipamorelin) to model dual-receptor GH axis activation
- Investigating DPP-IV resistance of modified GHRH analogs is a key endpoint
Final Takeaway
CJC-1295 with DAC and CJC-1295 without DAC represent two structurally related yet functionally distinct instruments for investigating GHRH receptor biology and GH axis physiology in preclinical models. The DAC modification fundamentally extends the compound's half-life through albumin binding, enabling studies of sustained tonic GH and IGF-1 elevation, while the No DAC variant preserves the pulsatile kinetic architecture that more closely replicates endogenous GHRH signaling. Researchers selecting between these two variants should be guided by their specific study endpoints—whether the question concerns duration of GH axis stimulation, pulsatile release dynamics, combination receptor strategies, or fundamental pharmacokinetic modeling. Both variants continue to appear in the preclinical literature as valuable reference tools for understanding one of the most important axes in endocrine biology.
Sources & Further Reading
- Jetté L et al. — "hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog" — Journal of Clinical Endocrinology & Metabolism (2005)
- PubMed Search — GHRH analog pulsatile growth hormone preclinical models
- PubMed Search — CJC-1295 growth hormone-releasing hormone research
- PubMed Search — Albumin-binding peptide half-life extension strategies
- PubMed Search — Mod GRF 1-29 DPP-IV stability and GHRH receptor biology
Disclaimer: This article is for informational and research purposes only. The products mentioned are intended for laboratory and research use only and are not for human consumption. These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease.
Originally published at https://www.sourcepeptides.co/2026/08/08/cjc-1295-with-dac-vs-no-dac-researchers-guide-to-structural-differences-release-kinetics-preclinical-study-comparisons-2026/.
Top comments (0)